Devyser Diagnostics AB (publ) (STO: DVYSR)

Market Cap	2.13B
Revenue (ttm)	198.10M
Net Income (ttm)	-71.40M
Shares Out	16.51M
EPS (ttm)	-4.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,075
Average Volume	22,849
Open	132.00
Previous Close	132.50
Day's Range	127.50 - 132.00
52-Week Range	77.00 - 141.00
Beta	0.76
RSI	60.79
Earnings Date	Feb 13, 2025

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as acce...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 118
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2023, Devyser Diagnostics AB's revenue was 169.30 million, an increase of 33.73% compared to the previous year's 126.60 million. Losses were -53.60 million, 16.5% more than in 2022.